Effect Of Actos Diabetes On Cardiovascular Disease
It is known that such disease as type 2 diabetes is associated with a two- to four-fold increase in cardiovascular disease and also other cardiovascular risk factors, for example, cholesterol disorders and high blood pressure. Moreover, the main cause of mortality and morbidity for patients with type 2 diabetes is heart disease.
PROspective PioglitAzone Clinical Trial In MacroVascular Events Study (PROactive) is a European clinical trial assessing the effects of Actos drug (pioglitazone HCl) on mortality and morbidity associated with cardiovascular disease progression in treating diabetes. Issue of Diabetes Care published the study design of PROactive in the July 2004.
This trial involved 5,238 patients with experience of one or more cardiovascular
events such as a heart attack, stroke or coronary artery bypass surgery. John Dormandy, M.D., professor of Vascular Sciences at St. George’s Hospital, London, and chairman of the PROactive study steering committee suggested that compared to major studies recent studies showed Actos medication had a favorable effect on markers of cardiovascular risk. And he hopes that through PROactive they will manage to reveal if it is possible to translate into a reduction in cardiovascular mortality and morbidity in a high-risk population of patients with type 2 diabetes.
According to John Yates, M.D., M.R.C.P., president, Takeda Global Research & Development, physicians encounter challenges (cardiovascular risk) while treating patients with diabetes medication. And he noticed that because of PROactive there should be produced important insights into the role of Actos drug in the management of cardiovascular disease.
One can always order Actos 15 mg and Actos 30 mg in our online pharmacy.
